Zynerba Pharmaceuticals (ZYNE) Posts Earnings Results, Beats Estimates By $0.02 EPS

Zynerba Pharmaceuticals (NASDAQ:ZYNE) announced its earnings results on Wednesday. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02, MarketWatch Earnings reports.

ZYNE opened at $11.96 on Friday. The firm has a market capitalization of $252.06 million, a price-to-earnings ratio of -4.58 and a beta of 5.62. Zynerba Pharmaceuticals has a 12-month low of $2.75 and a 12-month high of $13.33.

A number of research firms have issued reports on ZYNE. HC Wainwright reiterated a “buy” rating on shares of Zynerba Pharmaceuticals in a report on Monday, March 18th. Zacks Investment Research upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Friday, March 22nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $11.00 price objective on shares of Zynerba Pharmaceuticals in a report on Thursday, March 7th. ValuEngine upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, April 30th. Finally, Roth Capital began coverage on Zynerba Pharmaceuticals in a report on Tuesday, April 30th. They issued a “buy” rating and a $36.00 price objective for the company. Seven analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $18.52.

ILLEGAL ACTIVITY WARNING: This piece was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.baseballdailydigest.com/news/2019/05/10/zynerba-pharmaceuticals-zyne-posts-earnings-results-beats-estimates-by-0-02-eps.html.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder.

Read More: Intrinsic Value

Earnings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.